Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Completed 4Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 52Brain Neoplasms 28Glioma 22Gliosarcoma 19Melanoma 18Astrocytoma 17Central Nervous System Neoplasms 11Oligodendroglioma 10Neoplasms 9Neoplasm Metastasis 8Recurrence 6Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Lymphoma 4Ependymoma 4Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Sarcoma, Ewing 2Neurologic Manifestations 2Neuroectodermal Tumors, Primitive 2Neoplasms, Second Primary 2Meningeal Carcinomatosis 2Medulloblastoma 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Tetanus 1Spinal Cord Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Recurrent 1

Interventions

thymoglobulin 2Thiotepa 2Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Etoposide 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sodium thiosulfate 1ribociclib 1omburtamab I-131 1lexatumumab 1ganitumab 1fludarabine phosphate 1copanlisib 1bempegaldesleukin 1X-Rays 1Vincristine 1Topotecan 1Temozolomide 1Tacrolimus 1Specimen Handling 1Rituximab 1Receptor Protein-Tyrosine Kinases 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Polymerase Chain Reaction 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma × Temozolomide × Clear all
NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Novartis

Phase 1 Terminated
12 enrolled
CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡